Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Discontinued Operations (2023 - 2025)

Historic Cash from Discontinued Operations for Legend Biotech (LEGN) over the last 3 years, with Q1 2025 value amounting to -$106.3 million.

  • Legend Biotech's Cash from Discontinued Operations fell 455830.54% to -$106.3 million in Q1 2025 from the same period last year, while for Mar 2025 it was -$281.6 million, marking a year-over-year change of. This contributed to the annual value of -$144.0 million for FY2024, which is 6337.61% up from last year.
  • As of Q1 2025, Legend Biotech's Cash from Discontinued Operations stood at -$106.3 million, which was down 455830.54% from -$82.1 million recorded in Q4 2024.
  • In the past 5 years, Legend Biotech's Cash from Discontinued Operations registered a high of $2.4 million during Q1 2024, and its lowest value of -$106.3 million during Q1 2025.
  • Moreover, its 3-year median value for Cash from Discontinued Operations was -$88.9 million (2023), whereas its average is -$70.4 million.
  • As far as peak fluctuations go, Legend Biotech's Cash from Discontinued Operations soared by 1418.47% in 2024, and later plummeted by 455830.54% in 2025.
  • Over the past 3 years, Legend Biotech's Cash from Discontinued Operations (Quarter) stood at -$95.6 million in 2023, then increased by 14.18% to -$82.1 million in 2024, then fell by 29.49% to -$106.3 million in 2025.
  • Its Cash from Discontinued Operations stands at -$106.3 million for Q1 2025, versus -$82.1 million for Q4 2024 and $2.4 million for Q1 2024.